Recombinant Lactococcus lactis can make the difference in antigen-specific immune tolerance induction, the Type 1 Diabetes case.

Abstract

Especially in western civilizations, immune diseases that are driven by innocuous (auto- or allo-) antigens are gradually evolving to become pandemic threats. A particularly poignant example is type 1 diabetes, where young children are confronted with the perspective and consequences of total pancreatic β-cell destruction. Along these disquieting observations we find ourselves equipped with impressively accumulating molecular immunological knowledge on the ins and outs of these pathologies. Often, however, it is difficult to translate this wealth into efficacious medicines. The molecular understanding, the concept of oral tolerance induction, the benefit of using recombinant Lactococcus lactis therein and recent openings towards their clinical use may well enable turning all colors to their appropriate fields on this Rubik's cube.

• Authors: Sofie Robert, Lothar Steidler
• Journal: Microbial cell factories (Microb Cell Fact) Vol. 13 Suppl 1 Pg. S11 (Aug 29 2014) ISSN: 1475-2859 [Electronic] England
• PMID: 25185797 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Topics

• Diabetes Mellitus, Type 1 (immunology, pathology, therapy)
• Genetic Engineering
• Humans
• Immune Tolerance
• Immunity, Cellular
• Immunotherapy
• Insulin-Secreting Cells (metabolism)
• Lactococcus lactis (genetics, immunology)